ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$66.00 USD
+0.50 (0.76%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $66.05 +0.05 (0.08%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ANIP 66.00 +0.50(0.76%)
Will ANIP be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ANIP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIP
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
ANIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
Other News for ANIP
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET
ANI Pharmaceuticals Financial Report: Key Insights Revealed
ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension
ANI Pharmaceuticals announces launch of Baclofen Oral Suspension